03 March 2010
Elan to Present at the Cowen and Company Healthcare Conference| DUBLIN, Mar 03, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Cowen and Company Healthcare Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time and 1:45 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will ... |
|
28 February 2010
Neuroimaging Technique Supports Reduction in Amyloid-Beta in Brains of Patients Suffering from Alzheimer's Disease Treated with Bapineuzumab| Phase II Study Published Online in LancetNeurology
DUBLIN, Feb 28, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheime... |
|
25 February 2010
Elan Announces Filing of Annual Report on Form 20-F for Year Ended December 31, 2009| DUBLIN, Feb 25, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2009. The Form 20-F is available on Elan's website at www.elan.com. Elan will provide to all holders of Elan securities, upon request and free of charge, a hard copy of our complete audited financial statements included in our Form 20-F.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company commit... |
|
10 February 2010
Elan Reports Fourth Quarter and Full-Year 2009 Financial Results| DUBLIN, Feb 10, 2010 (BUSINESS WIRE) -- Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.
Elan CEO Kelly Martin said, "during 2009, as the biotechnology industry continued to change significantly, we advanced our multi-year strategy for evolving the company. Our strategic transaction with Johnson & Johnson, now our largest shareholder, accelerated our positioning as a company that vigorously invests in sci... |
|
27 January 2010
Elan Announces Webcast of Fourth Quarter and Full Year 2009 Financial
Results| DUBLIN, Jan 27, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, February 10, at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. GMT with the investment community to discuss Elan's
fourth quarter and full year 2009 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over
the Interne... |
|
25 January 2010
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA(TM)
(Dalfampridine) Extended Release Tablets| AMPYRA(TM) APPROVED USING ELAN'S PROPRIETARY MXDAS(TM) (MATRIX DRUG ABSORPTION SYSTEM) DRUG DELIVERY TECHNOLOGYDUBLIN, Ireland, Jan 25, 2010 (BUSINESS WIRE) -- Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE:
ELN) today issued the following statement regarding the U.S. Food and
Drug Administration (FDA) approval of AMPYRA(TM) (dalfampridine)
as a treatment to improve walking in patients with multiple sclerosis
(MS). This was demonstrated by ... |
|
11 January 2010
World-Renowned Yogi Baron Baptiste Unveils New Program to Help People with Multiple Sclerosis| -- My MS Yoga is designed to help people better manage one of the most common neurological disorders, which often strikes in the prime of life --CAMBRIDGE, Mass., Jan 11, 2010 (BUSINESS WIRE) -- Baron Baptiste, bestselling author and founder of Baptiste Power Vinyasa Yoga, and Dr. Elliot Frohman, one of the world's leading authorities on multiple sclerosis (MS), have teamed up to develop My MS Yoga, a new program created especially for people with multiple sclerosis. My MS Yoga is an at-home exe... |
|
05 January 2010
Elan to Present at the 2010 J.P. Morgan Healthcare Conference| DUBLIN, Jan 05, 2010 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the 28th Annual J.P. Morgan Healthcare Conference, on Wednesday, January 13, 2010, at 9:00 a.m. Pacific Time, noon Eastern Time and 5:00 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at http://www.elan.com, then clicking on the event icon. Following the live webcast, an archived versi... |
|
15 December 2009
Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease| Two Highest Doses Removed from Phase II Trial, Lowest Dose Continues as Planned
DUBLIN, Dec 15, 2009 (BUSINESS WIRE) -- Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer's disease. The AD201 study is evaluating three dose levels of ELND005 compared to placebo in 353 patients.
Patients wi... |
|
14 December 2009
Elan Drug Technologies Announces First Japanese Approval of Product Using Its NanoCrystal® Technology| DUBLIN--(BUSINESS WIRE)--Dec. 14, 2009--
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE:
ELN) announces the approval by the Japanese Ministry of Health, Labour
and Welfare of EMEND® (aprepitant) for the treatment of
cancer chemotherapy-induced nausea and vomiting. EMEND®,
which was developed by a subsidiary of Merck & Co Inc., Whitehouse
Station, N.J., USA and licensed to Ono Pharmaceuticals Co., Ltd. for the
Japanese m... |
|
09 December 2009
Elan to Present at Deutsche Bank Securities Biotech Boston Confab Conference| DUBLIN, Dec 09, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Deutsche Bank Securities Biotech Boston Confab Conference, on Tuesday, December 15, 2009, at 10:30 a.m. Eastern Time and 3:30 p.m. GMT.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the pres... |
|
04 December 2009
Elan Drug Technologies Announces Submission by Janssen-Cilag of Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia using Elan's NanoCrystal® technology| DUBLIN, Dec 04, 2009 (BUSINESS WIRE) -- Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE:
ELN) announced that Janssen-Cilag has submitted a Marketing
Authorisation Application (MAA) to the European Medicines Agency for
paliperidone palmitate for the treatment of Schizophrenia. Paliperidone
palmitate, an investigational, once-monthly atypical antipsychotic
injection, utilises Elan Drug Technologies NanoCrystal®
technology.
The... |
|
10 November 2009
Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference| DUBLIN, Ireland, Nov 10, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Lazard Capital Markets 6th Annual Healthcare
Conference, on Tuesday, November 17, 2009 at; 9:55 a.m. Eastern Time and
2:55 p.m. GMT.
Interested parties may access a live audio web cast of the presentation
by visiting the Investor Relations section of the Elan website at www.elan.com,
then clicking on the event icon. Following the ... |
|
29 October 2009
Elan Corporation Plc Announces Expiration of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011| DUBLIN--(BUSINESS WIRE)--Oct. 29, 2009--
Elan Corporation, plc (NYSE: ELN) ("Elan") today announced the
expiration and final results of the tender offer for the 7¾% Senior
Fixed Rate Notes due 2011 (CUSIP No. 284138AC8) (the “Notes”) issued by
its wholly-owned subsidiaries, Elan Finance public limited company and
Elan Finance Corp. (the “Co-Issuers”). The tender offer expired on
October 28, 2009, at 11:59 p.m., New York City time (the "Expiration
... |
|
27 October 2009
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease| DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Oct. 27, 2009--
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today
announced data showing that treatment with TYSABRI®
(natalizumab) significantly reduced the rate of hospitalization compared
with placebo in patients with moderate–to–severe Crohn’s disease during
both induction and maintenance treatment. These results were obtained
from retrospective subset analyses of three registrational Phas... |
|
21 October 2009
Elan Reports Third Quarter 2009 Financial Results| DUBLIN--(BUSINESS WIRE)--Oct. 21, 2009--
Elan Corporation, plc today reported its third quarter 2009 financial
results.
Elan CEO Kelly Martin said, “The third quarter of 2009 proved to be a
time of significant transformation for Elan. Completion of the Johnson &
Johnson transaction and the subsequent refinancing of our balance sheet
provide strategic flexibility and financial stability for the company.”
He added, R... |
|
19 October 2009
Elan to Highlight Tysabri Data in Crohn's Disease at the American College of Gastroenterology Annual Scientific Meeting| DUBLIN, Ireland & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 19, 2009--
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDQ: BIIB) today
announced multiple presentations at the American College of
Gastroenterology (ACG) Annual Scientific Meeting, taking place October
23-28 in San Diego.
The posters and presentations during ACG will highlight TYSABRI®
(natalizumab) data in treating Crohn’s Disease. During a plenary session
... |
|
14 October 2009
Elan Corporation PLC Announces Results to Date of Tender Offer for 7¾% Senior Fixed Rate Notes Due 2011| DUBLIN, Oct 14, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE:ELN) ("Elan") today announced the results as
of the early tender date of the tender offer for the 7¾% Senior Fixed
Rate Notes due 2011 (CUSIP No. 284138AC8) (the "Notes") issued by its
wholly-owned subsidiaries, Elan Finance public limited company and Elan
Finance Corp. (the "Co-Issuers").
As of 11:59 p.m., New York City time, on October 13, 2009, the
Co-Issuers had received tenders in re... |
|
07 October 2009
Elan Announces Webcast of Third Quarter 2009 Financial Results| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 7, 2009--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Wednesday, October 21, 2009 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan’s third quarter 2009 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultan... |
|
29 September 2009
Elan Corporation plc Announces Pricing of New 2016 Senior Notes| DUBLIN--(BUSINESS WIRE)--Sep. 29, 2009--
Elan Corporation, plc ("Elan") today announced the pricing of the
offering of US$625 million aggregate principal amount of senior notes
due 2016 (“New Notes”) by its wholly-owned subsidiaries, Elan Finance
public limited company and Elan Finance Corp. The New Notes will carry a
coupon of 8.75% per annum, payable semi-annually in arrears beginning
April 15, 2010. The offering is expected to close on October 2, ... |
|
29 September 2009
Elan Corporation Plc Announces Cash Tender for Outstanding US$850M in Aggregate Principal Amount of 2011 Fixed Rate Notes| DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 29, 2009--
Elan Corporation, plc ("Elan") today announced that its wholly-owned
subsidiaries, Elan Finance public limited company and Elan Finance
Corp., are commencing a cash tender offer (the “Tender Offer”) for the
outstanding US$850 million in aggregate principal amount of their 7 3/4%
senior fixed rate notes due 2011 (the “2011 Fixed Rate Notes”). The
Tender Offer is being made pursu... |
|
29 September 2009
Elan Corporation plc Announces Intent to Offer US$600M in Aggregate Principal Amount of Senior Fixed Rate Notes Due 2016| DUBLIN--(BUSINESS WIRE)--Sep. 29, 2009--
Elan Corporation, plc ("Elan") today announced that its wholly-owned
subsidiaries, Elan Finance public limited company and Elan Finance
Corp., intend to offer, subject to market conditions, US$600 million in
aggregate principal amount of senior fixed rate notes due 2016 (the “New
Notes”). The New Notes will be offered to qualified institutional buyers
pursuant to Rule 144A under the Securities Act of 1933, as ... |
|
17 September 2009
Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment| NEW BRUNSWICK, N.J., & DUBLIN--(BUSINESS WIRE)--Sep. 17, 2009--
Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today
announced that JANSSEN Alzheimer Immunotherapy, a newly formed
subsidiary of Johnson & Johnson, has completed the acquisition of
substantially all of the assets and rights of Elan related to its
Alzheimer’s Immunotherapy Program (AIP). In addition, Johnson & Johnson,
through its affiliate, Janssen Pharmaceutical, has ... |
|
14 September 2009
Elan Cures Breach of Tysabri® Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson| DUBLIN, Sep 14, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it has cured an
unintended breach of its Tysabri Collaboration Agreement with Biogen
that had been identified by the United States District Court for the
Southern District of New York. Elan's previously announced transaction
with Johnson & Johnson has been amended to eliminate in its entirety the
Strategic Financing and Collaboration Agreement that was the subjec... |
|
11 September 2009
Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis|
-- TYSABRI redefines expectations of multiple sclerosis therapy for
some patients --
DUSSELDORF, Germany--(BUSINESS WIRE)--Sep. 11, 2009--
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today
announced data presented at the 25th Congress of the European Committee
for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the
potential of TYSABRI® (natalizumab) to redefine successful
multiple sclerosis (MS) the... |
|
10 September 2009
Elan to Present at Morgan Stanley Global Healthcare Unplugged Conference| DUBLIN--(BUSINESS WIRE)--Sep. 10, 2009--
Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Morgan Stanley Global Healthcare Unplugged Conference in New
York, NY, on Monday, September 14, 2009, at 2:45 p.m. British Summer
Time; and 9:45 a.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation
by visiting the Investor Relations section of the Elan website at www.elan.com,
then... |
|
03 September 2009
Elan Issues Statement Regarding Federal Court Ruling on Tysabri(R) Collaboration Agreement| DUBLIN--(BUSINESS WIRE)--Sep. 3, 2009--
Elan Corporation, plc (NYSE:ELN) today issued the following statement
regarding a ruling made by the United States District Court for the
Southern District of New York that Elan has breached its Collaboration
Agreement with Biogen Idec for the development and marketing of Tysabri:
We respect the Court’s decision and the expedited attention in this
matter. We are committed to working with Johnson... |
|
06 August 2009
Elan Files Declaratory Suit Against Biogen Idec; Company Has Not Breached Tysabri® Collaboration Agreement| DUBLIN--(BUSINESS WIRE)--Aug. 6, 2009--
Elan Corporation, plc (NYSE:ELN) today announced that it has filed suit
against Biogen Idec Inc. in Federal Court in New York seeking
declaratory and injunctive relief that certain aspects of Elan’s
recently announced transaction with affiliates of Johnson & Johnson (the
“Transaction”) comply with Elan’s Collaboration Agreement with Biogen
Idec for the development and marketing of Tysabri (the “Collaboration
... |
|
03 August 2009
Elan Drug Technologies announces first approval of a long acting injectable formulation using NanoCrystal® Technology| Fifth product approved by the US FDA licensing Elan's NanoCrystal® technology for various formulations
DUBLIN--(BUSINESS WIRE)--Aug. 3, 2009--
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE:
ELN) announces the first approval of a long-acting injectable
formulation using Elan Drug Technologies’ proprietary NanoCrystal®
technology.
Late last week, Janssen, a division of Ortho-McNeil-Janssen
Pharmaceuticals, announced th... |
|
21 July 2009
Elan Reports Second Quarter 2009 Financial Results| DUBLIN, Jul 21, 2009 (BUSINESS WIRE) -- Elan Corporation, plc today reported its second quarter 2009 financial
results.
Elan CEO Kelly Martin said, "During the first six months of 2009, we
grew revenues, added an additional approach to Alzheimer's disease and
successfully completed our strategic review with the announcement of a
transformative transaction with Johnson & Johnson. Our focus will remain
squarely on a disciplined and continuous investment in ... |
|
14 July 2009
Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease | VIENNA, Austria, July 14 /PRNewswire-FirstCall/ -- Elan Corporation, plc
(NYSE: ELN) and Wyeth (NYSE: WYE) presented information this week at the
Alzheimer Association 2009 International Conference on Alzheimer's Disease
(ICAD 2009) from seven posters and one podium presentation about the growing
burden of care and costs associated with Alzheimer's disease (AD) and how to
measure them. This information sheds light on the impact of AD, which, as the
population ages, will place a signif... |
|
13 July 2009
Elan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid| Presentations at 2009 Alzheimer's Association International Conference on Alzheimer's Disease Support Ongoing Phase 2 TrialDUBLIN & TORONTO & VIENNA, Jul 13, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX:
TTH, NASDAQ: TTHI) today presented Phase 1 data demonstrating that
treatment with ELND005 (scyllo-inositol formerly known as AZD-103),
achieves desired concentrations in human brain tissue and cerebrospinal
fluid ... |
|
08 July 2009
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting| DUBLIN--(BUSINESS WIRE)--Jul. 8, 2009--
Elan Corporation, plc (NYSE: ELN) today announced multiple presentations
at the 2009 Alzheimer’s Association International Conference on
Alzheimer’s Disease (ICAD 2009) in Vienna, Austria.
Elan and investigators will be present from the Alzheimer's
Immunotherapy Program (AIP), a joint research, development and
commercialization program between Wyeth and Elan that includes
investigational clinical... |
|
07 July 2009
Elan Announces Webcast of Second Quarter 2009 Financial Results| DUBLIN--(BUSINESS WIRE)--Jul. 7, 2009--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a
conference call on Tuesday, July 21, 2009 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan’s second quarter 2009 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadc... |
|
02 July 2009
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment| NEW BRUNSWICK, New Jersey and DUBLIN, July 2 /PRNewswire/ --
- First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline
- Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through... |
|
11 June 2009
Elan Announces Date of 2009 Annual General Meeting and Changes in Board of Directors| Vaughn Bryson, Richard Pilnik and Jack Schuler to Join the Elan Board
DUBLIN--(BUSINESS WIRE)--Jun. 11, 2009--
Elan Corporation, plc (NYSE: ELN) today announced the date of its 2009
Annual General Meeting (“the AGM”) and changes in the composition of its
Board of Directors.
Annual General Meeting
The 2009 AGM will be held in Dublin on July 16, 2009 at 10:00 a.m.,
British Summer Time (BST). The Notice of the Annual General Meeting wil... |
|
03 June 2009
Elan to Present at Goldman Sachs 30th Annual Global Healthcare Conference| DUBLIN--(BUSINESS WIRE)--Jun. 3, 2009--
Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Goldman Sachs 30th Annual Global Healthcare Conference in New
York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time;
and 2:30 p.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation
by visiting the Investor Relations section of the Elan website at www.elan.com,
then c... |
|
31 May 2009
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFa Therapy| DUBLIN, Ireland & CHICAGO, Ill., May 31, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) shared
data today that TYSABRI® (natalizumab) improved health
related quality of life (QOL) in Crohn's Disease (CD) patients who had
previously been exposed to or failed anti-TNFa therapy versus placebo.
These results were obtained from subset analyses of the Phase 3 ENACT-2
(Evaluation of Natalizumab as Continuous Therapy) and ... |
|
29 May 2009
Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer| SAN FRANCISCO & NEW YORK & DUBLIN--(BUSINESS WIRE)--May. 29, 2009--
Elan Corporation, plc (NYSE: ELN) announced today that Renee P.
Tannenbaum, Pharm.D., has joined the company as Executive Vice President
and Chief Commercial Officer. Dr. Tannenbaum will be based at Elan’s
South San Francisco campus and report to Elan President Carlos Paya, MD,
PhD.
Elan CEO Kelly Martin said that Dr. Tannenbaum was joining the company
at a special tim... |
|
12 May 2009
Elan Announces Change in Board of Directors| DUBLIN--(BUSINESS WIRE)--May. 12, 2009--
Elan Corporation, plc (NYSE:ELN) today announced the appointment of
Richard D. Pilnik, former Chief Marketing Officer of Eli Lilly and
Company, as non-executive director of the Company. Mr. Pilnik will join
the Board effective June 1st.
Mr. Kyran McLaughlin, Chairman of Elan, said, “The Board is delighted to
welcome Mr. Pilnik, who is an exceptionally talented, well-regarded and
accompli... |
|
28 April 2009
MRI Data Showing TYSABRI® Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology| -- Additional data suggests improvement in TYSABRI patients across clinical and patient-reported outcomes --
SEATTLE--(BUSINESS WIRE)--Apr. 28, 2009--
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today
announced results of a study demonstrating that TYSABRI®
(natalizumab) promoted regeneration and stabilization of damage done to
the myelin sheath, as measured by advanced MRI technology. Damage to the
myelin sheath causes the symptoms of... |
|
23 April 2009
Elan and Transition Therapeutics Receive Key Patent for Alzheimer's Disease Treatment with ELND005| DUBLIN & TORONTO--(BUSINESS WIRE)--Apr. 23, 2009--
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics
Inc. (TSX: TTH, NASDAQ:TTHI) today announced the United States
Patent and Trademark Office issued US patent number 7,521,481 on April
21, 2009. The patent is entitled “Methods of Preventing, Treating and
Diagnosing Disorders of Protein Aggregation,” and generally claims
methods for treating Alzheimer’s disease comprising administering
... |
|
22 April 2009
Elan Reports First Quarter 2009 Financial Results| DUBLIN--(BUSINESS WIRE)--Apr. 22, 2009--
Elan Corporation, plc, today reported its first quarter 2009 financial
results, highlighted by a 14% increase in revenue to $245.1 million and
Adjusted EBITDA losses reduced by 59% to $6.0 million, compared to the
first quarter of 2008, and significant advances in the company’s
Biopharmaceuticals business.
Elan CEO Kelly Martin said that the company continued advancing its
science toward... |
|
09 April 2009
Elan Announces Webcast of First Quarter 2009 Financial Results| DUBLIN, Apr 09, 2009 (BUSINESS WIRE) -- Elan Corporation, plc (NYSE: ELN) today announced that it will host a
conference call on Wednesday, April 22, 2009 at 8:30 a.m. Eastern Time
(ET), 1:30 p.m. British Summer Time (BST) with the investment community
to discuss Elan's first quarter 2009 financial results, which will be
released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over
th... |
|
02 April 2009
Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols| DUBLIN & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Apr. 2, 2009--
Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) today announced
that the companies will discontinue the highest of three dosing
regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab
in patients with mild to moderate Alzheimer’s disease (AD) who do not
carry the Apolipoprotein E4 (ApoE4) allele (non-carriers). ApoE4 is a
known genetic risk factor for develo... |
|
30 March 2009
Elan Announces Filing of Annual Report for Year Ended December 31, 2008| DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 30, 2009--
Elan Corporation, plc (NYSE:ELN) today announced the publication and
filing of its Annual Report for the fiscal year ended December 31, 2008.
The Annual Report along with Elan's Form 20-F for the year ended
December 31, 2008 (as filed with the Securities and Exchange Commission
on February 27, 2009) are available on Elan's website at www.elan.com.
Elan will provide to all holders of Elan securities, u... |
|
12 March 2009
Elan to Present at Cowen and Company 29th Annual Health Care Conference| DUBLIN--(BUSINESS WIRE)--Mar. 12, 2009--
Elan Corporation, plc (NYSE: ELN) today announced that it will present
at the Cowen and Company 29th Annual Health Care Conference
in Boston, MA on Thursday, March 19, 2009 at 8:05 a.m. PDT, 11:05 a.m.
EDT, 3:05 p.m. GMT. The presentation will be followed by a breakout
session.
Interested parties may access a live audio web cast of the presentation
by visiting the Investor Relations section of... |
|
25 February 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process| DUBLIN--(BUSINESS WIRE)--Feb. 25, 2009--
Elan Corporation, plc (NYSE: ELN) announced today that, as previously
guided, and as part of its ongoing efforts to consistently and
rigorously manage its overall cost base and direct additional investment
toward its promising and late stage pipeline, it will refine its
business operations and functions to realize greater efficiencies and
deepen its commitment and focus to key and strategic areas.
... |
|
10 February 2009
Elan Reports Fourth Quarter and Full-Year 2008 Results| DUBLIN, Feb 10, 2009 (BUSINESS WIRE) -- Elan Corporation, plc, today reported its fourth quarter and full-year
2008 results, highlighted by a 32% increase in full-year 2008 revenue to
$1.0 billion, compared to $759.4 million for the same period in 2007,
and significant advances in the Company's biopharmaceutical and drug
technology business units.
Elan chief executive officer Kelly Martin said that in 2008 Elan made
tangible, measurable progress in moving... |
|
09 February 2009
MS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology| TYSABRI is the first product approved for the treatment of MS to show that significantly more patients are living a life free of disease activityCAMBRIDGE, Mass. & DUBLIN, Feb 09, 2009 (BUSINESS WIRE) -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today
announced five-times as many multiple sclerosis (MS) patients taking
TYSABRI® (natalizumab) were free from disease activity versus
placebo in the overall patient population. Results from this
r... |
|
13 January 2009
Elan to Review Strategic Business Alternatives| DUBLIN, Ireland & NEW YORK, & SAN FRANCISCO--(BUSINESS WIRE)--Jan. 13, 2009--Elan Corporation, plc (NYSE: [ELN]) announced today that the
Board of Directors has engaged Citigroup Global Markets Inc. to conduct,
in conjunction with executive management and other external advisors, a
review of the Company's strategic alternatives. The goal is to secure
access to the necessary financial resources and commercial
infrastructure to allow Elan to accelerat... |
|
13 January 2009
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 13, 2009--Elan Corporation, plc (NYSE:ELN) today clarified recent reports that the
duration of the bapineuzumab Phase 3 clinical trials may be extended.
The protocols for the four Phase 3 trials for bapineuzumab, which are
approved by regulatory authorities, are designed for patients to
participate for a duration of 18 months. The planned duration of the
trials has not changed since the program was announced in Decembe... |
|
12 January 2009
Elan Announces Webcast of Fourth Quarter and Full Year 2008 Financial Results| DUBLIN, IRELAND--(BUSINESS WIRE)--Jan. 12, 2009--Elan Corporation, plc (NYSE:ELN) announced today that it will host a
conference call on Tuesday, February 10, 2009 at 8:30 a.m. Eastern
Standard Time (EST), 1:30 p.m. Greenwich Mean Time (GMT) with the
investment community to discuss Elan's fourth quarter and full year 2008
financial results, which will be released before the European and U.S.
financial markets open.
Live audio of the confere... |
|
RSS Feeds | 
E-mail Alerts | 
Contact IR